Pharmaceutical composition

By incorporating specific components like magnesium silicate and glycine with naproxen and ethenzamide, the formulation stability is enhanced, addressing the issue of appearance changes in the pharmaceutical composition.

JP2024163039APending Publication Date: 2024-11-21TAISHO PHARMACEUTICAL CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024072699
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-04-26
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The interaction between naproxen and ethenzamide in a pharmaceutical composition leads to formulation instability, specifically changes in appearance over time, which is not well understood in existing technologies.

Method used

A pharmaceutical composition is formulated with naproxen or its salt, ethenzamide or its salt, and specific components such as magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, aluminum hydroxide gel, glycine, lactose, hydroxypropylcellulose, and hypromellose, in specific ratios and configurations to maintain stability.

Benefits of technology

The composition achieves excellent storage stability by suppressing changes in appearance, ensuring the formulation remains stable over time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163039000001
    Figure 2024163039000001
  • Figure 2024163039000002
    Figure 2024163039000002
  • Figure 2024163039000003
    Figure 2024163039000003
Patent Text Reader

Abstract

To provide a pharmaceutical composition containing naproxen or a salt thereof and ethenzamide or a salt thereof, exhibiting high storage stability.SOLUTION: A pharmaceutical composition contains (A) naproxen or a salt thereof, (B) ethenzamide or a salt thereof and (C) at least one selected from the group consisting of the following (c1), (c2), and (c3): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, and aluminum hydroxide gel; (c2) glycine; and (c3) at least one selected from the group consisting of lactose, hydroxypropylcellulose, and hypromellose.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition containing naproxen or a salt thereof. [Background technology]

[0002] Naproxen is a propionic acid-based nonsteroidal antipyretic, analgesic, and anti-inflammatory drug (NSAIDs), which has anti-inflammatory, analgesic, and antipyretic effects by inhibiting the biosynthesis of prostaglandins, which cause fever and inflammation (Non-Patent Document 1). Currently, NSAIDs are widely used as the main ingredient of antipyretic analgesics and cold medicines not only for medical use but also for over-the-counter medicines, because they have relatively few side effects. Therefore, it is expected that naproxen will be applied to over-the-counter medicines. Naproxen has the above-mentioned pharmacological action, and studies are being conducted to further enhance the efficacy of naproxen itself. For example, it has been reported that the antipyretic, analgesic, and anti-inflammatory effects are enhanced by combining naproxen with a specific pharmaceutical ingredient (Patent Documents 1 and 2). In addition, naproxen is a drug with excellent formulation stability, but it is known that when it is mixed with the expectorant ingredient ambroxol, it causes a change in composition, and that the change in composition can be prevented by adding a basic ingredient (Patent Document 2). Furthermore, it has been reported that the disintegration property is improved by combining naproxen with a basic compound such as an antacid (Patent Document 3). However, it is not known whether an interaction that directly affects the stability of a formulation occurs when naproxen and ethenzamide are combined in a pharmaceutical composition. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2018-76305 A [Patent Document 2] JP 2018-76306 A [Patent Document 3] JP 2018-76310 A [Non-patent literature]

[0004] [Non-Patent Document 1] Nikesan Tablets 100mg Interview Form Summary of the Invention [Problem to be solved by the invention]

[0005] The present inventors mixed naproxen with the antipyretic and analgesic ingredient ethenzamide and confirmed the storage stability of the preparation, and surprisingly discovered that the appearance changed over time.

[0006] Therefore, an object of the present invention is to provide a pharmaceutical composition which contains naproxen or a salt thereof and ethenzamide or a salt thereof and has excellent storage stability. [Means for solving the problem]

[0007] Means of the Invention The present inventors have conducted various investigations to solve the above problems and have found that the change in appearance can be suppressed by blending a specific component, thereby completing the present invention.

[0008] That is, the present invention (1)(A) naproxen or a salt thereof, (B) ethenzamide or a salt thereof, and (C) A pharmaceutical composition comprising at least one selected from the group consisting of the following (c1), (c2), and (c3): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, and aluminum hydroxide gel; (c2) Glycine (c3) at least one selected from the group consisting of lactose, hydroxypropyl cellulose, and hypromellose (2) The pharmaceutical composition according to (1), wherein the content ratio of the component (A) to the component (B) is 0.125 to 150 parts by mass of the component (B) per 1 part by mass of the component (A). (3) The pharmaceutical composition according to (1) or (2), wherein the content of the component (C) is 0.01 to 2 parts by mass per 1 part by mass of the total amount of the components (A) and (B). (4) The pharmaceutical composition according to any one of (1) to (3), which is a solid formulation. (5) A method for inhibiting discoloration of a pharmaceutical composition containing (A) naproxen or a salt thereof and (B) ethenzamide or a salt thereof, comprising the steps of: A method for inhibiting discoloration of the pharmaceutical composition, comprising comprising comprising containing at least one member selected from the group consisting of the following (C) (c1), (c2), and (c3): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, and aluminum hydroxide gel; glycine (c2) Glycine (c3) at least one selected from the group consisting of lactose, hydroxypropyl cellulose, and hypromellose It is. Effect of the Invention

[0009] According to the present invention, it is possible to provide a pharmaceutical composition containing naproxen or a salt thereof and ethenzamide or a salt thereof, which has excellent storage stability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The pharmaceutical composition containing naproxen or a salt thereof of the present invention will be described in detail below.

[0011] <Component (A)> The component (A) in the pharmaceutical composition of the present invention includes not only naproxen but also pharma- ceutical acceptable salts of naproxen and solvates with water, alcohol, etc. These are known compounds and can be produced by known methods, or commercially available products can be used. In the present invention, naproxen or a salt thereof is preferably naproxen. Naproxen used in the pharmaceutical composition of the present invention has the chemical name (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid, the molecular formula is C14H14O3, and the molecular weight is 230.26. Naproxen is a propionic acid-based nonsteroidal anti-inflammatory analgesic already known as an anti-inflammatory analgesic, and is widely used for the purposes of anti-inflammation, analgesia, and fever reduction in diseases such as rheumatoid arthritis, osteoarthritis, gout attacks, ankylosing spondylitis, lower back pain, shoulder periarthritis, neck-shoulder-arm syndrome, tendonitis, tendonitis, dysmenorrhea, and shingles, as well as anti-inflammation and analgesia after trauma and surgery, and anti-inflammation and analgesia after tooth extraction and minor surgery in the dental and oral surgery fields. The naproxen salt in the pharmaceutical composition of the present invention may be any pharma- ceutically acceptable salt, and examples thereof include sodium salt, potassium salt, ammonium salt, meglumine salt, Tris salt, and salts of basic amino acids. The content of naproxen or a salt thereof in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, and may be appropriately determined depending on the sex, age, symptoms, etc. of the user. The daily dose for an adult aged 15 years or older is usually 10 to 1,200 mg, preferably 15 to 900 mg, and more preferably 20 to 600 mg. The content of naproxen relative to the total mass of the pharmaceutical composition is preferably 1 to 90 mass%, more preferably 5 to 80 mass%, further preferably 5 to 70 mass%, and particularly preferably 9 to 60 mass%.

[0012] <(B) component> Ethenzamide (2-ethoxybenzamide) in the pharmaceutical composition of the present invention is a salicylic acid-based nonsteroidal anti-inflammatory drug (NSAIDs) and is used as an antipyretic and analgesic ingredient. The salt of ethenzamide in the pharmaceutical composition of the present invention may be any pharma- ceutical acceptable salt, and examples thereof include sodium salt, potassium salt, ammonium salt, meglumine salt, tris salt, salt of a basic amino acid, and the like. The content of ethenzamide in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, and may be appropriately determined depending on the gender, age, symptoms, etc. of the recipient. The daily dosage for adults aged 15 years or older is preferably 150 to 1500 mg, more preferably 200 to 1500 mg, and even more preferably 250 to 1500 mg. Furthermore, the content of ethenzamide relative to the total mass of the pharmaceutical composition is preferably 4 to 90 mass%, more preferably 4 to 80 mass%, further preferably 4 to 70 mass%, and particularly preferably 4 to 65 mass%.

[0013] The total content of the components (A) and (B) contained in the pharmaceutical composition of the present invention is preferably 10 to 90% by mass, more preferably 30 to 90% by mass, and even more preferably 30 to 80% by mass. The content ratio of the components (A) and (B) is not particularly limited, but is preferably 0.125 to 150 parts by mass, more preferably 0.22 to 100 parts by mass, even more preferably 0.25 to 75 parts by mass, and particularly preferably 0.25 to 5 parts by mass of ethenzamide (B) per part by mass of naproxen (A).

[0014] <(C) component> In the combination of components (A) and (B), the coexistence of component (C) therewith results in a pharmaceutical composition that is less susceptible to changes in appearance. The component (C) in the pharmaceutical composition of the present invention is at least one selected from the group consisting of the following (c1), (c2), and (c3): The content of component (C) is preferably 5 to 90% by mass, more preferably 8 to 90% by mass, even more preferably 10 to 90% by mass, and particularly preferably 10 to 70% by mass, based on the total mass of the pharmaceutical composition of the present invention, from the viewpoint of suppressing changes in appearance due to the incorporation of naproxen and ethenzamide. Also, the content is preferably 0.1 to 2 parts by mass per part by mass of the total value of components (A) and (B).

[0015] <(c1) component> The component (c1) is a basic compound selected from magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, and dried aluminum hydroxide gel. The effect of suppressing appearance change is not observed with other basic compounds such as calcium hydrogen phosphate, synthetic aluminum silicate, and magnesium aluminometasilicate, and is an effect unique to the specific component of the present invention.

[0016] The daily dose (amount) of magnesium silicate in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 200-3000 mg, more preferably 600-3000 mg. The content of magnesium silicate in the pharmaceutical composition of the present invention is preferably 0.3-2 parts by mass, more preferably 0.35-2 parts by mass, even more preferably 0.43-1.5 parts by mass, and most preferably 0.71-1.43 parts by mass, per part by mass of the total value of the (A) component and the (B) component, from the viewpoint of suppressing the appearance change of naproxen and ethenzamide. In addition, the content of magnesium silicate in the pharmaceutical composition is preferably 20-70% by mass, more preferably 20-60% by mass, even more preferably 25-60% by mass, and particularly preferably 30-60% by mass.

[0017] The daily dose (amount of magnesium oxide) of the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 30 to 500 mg, more preferably 100 to 500 mg. The content of the magnesium oxide component in the pharmaceutical composition of the present invention is preferably 0.01 to 1 part by mass, more preferably 0.04 to 1 part by mass, even more preferably 0.1 to 0.5 parts by mass, particularly preferably 0.2 to 0.5 parts by mass, and most preferably 0.24 to 0.43 parts by mass, per part by mass of the total value of the components (A) and (B), from the viewpoint of suppressing the appearance change of naproxen and ethenzamide. The content of magnesium oxide is preferably 5 to 60% by mass, more preferably 10 to 60% by mass, even more preferably 10 to 50% by mass, and most preferably 10 to 30% by mass, relative to the total mass of the pharmaceutical composition.

[0018] The daily dose (amount) of magnesium carbonate in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 30 to 2000 mg, more preferably 130 to 2000 mg, and even more preferably 400 to 2000 mg. The content of the magnesium carbonate component in the pharmaceutical composition of the present invention is preferably 0.01 to 1 part by mass, more preferably 0.19 to 0.95 parts by mass, particularly preferably 0.43 to 0.95 parts by mass, and most preferably 0.71 to 0.95 parts by mass, per part by mass of the total value of the (A) component and the (B) component, from the viewpoint of suppressing the appearance change of naproxen and ethenzamide. The content of magnesium carbonate is preferably 10 to 60% by mass, more preferably 10 to 50% by mass, and even more preferably 15 to 50% by mass, relative to the total mass of the pharmaceutical composition.

[0019] The daily dose (amount) of magnesium hydroxide in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 60 to 1800 mg, more preferably 120 to 1800 mg. The content of magnesium hydroxide in the pharmaceutical composition of the present invention is preferably 0.01 to 1 part by mass, more preferably 0.1 to 0.5 parts by mass, and even more preferably 0.24 to 0.43 parts by mass, per part by mass of the total value of the (A) component and the (B) component, from the viewpoint of suppressing changes in appearance of naproxen and ethenzamide. The content of magnesium hydroxide is preferably 5 to 60% by mass, more preferably 10 to 60% by mass, particularly preferably 10 to 50% by mass, and most preferably 10 to 30% by mass, relative to the total mass of the pharmaceutical composition.

[0020] The daily dose (amount) of synthetic hydrotalcite in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 260 to 4000 mg, more preferably 800 to 4000 mg. The content of synthetic hydrotalcite in the pharmaceutical composition of the present invention is preferably 0.12 to 2 parts by mass, more preferably 0.3 to 1.9 parts by mass, particularly preferably 0.43 to 1.9 parts by mass, and most preferably 0.71 to 0.1.9 parts by mass, per part by mass of the total value of the (A) component and the (B) component, from the viewpoint of suppressing changes in appearance of naproxen and ethenzamide. The content of synthetic hydrotalcite is preferably 30 to 80% by mass, more preferably 30 to 70% by mass, and even more preferably 40 to 70% by mass, relative to the total mass of the pharmaceutical composition.

[0021] The dry aluminum hydroxide gel in the pharmaceutical composition of the present invention may be the dry aluminum hydroxide gel described in the "Japanese Pharmacopoeia, 17th Edition". The dry aluminum hydroxide gel may contain water such as bound water. The daily dose (formulation amount) of the dry aluminum hydroxide gel for those aged 15 years or older is not particularly limited, but is preferably 60 to 1000 mg, more preferably 200 to 1000 mg. It may also be used as an aluminum hydroxide gel. The content of the dry aluminum hydroxide gel in the pharmaceutical composition of the present invention is preferably 0.02 to 0.71 parts by mass, more preferably 0.09 to 0.71 parts by mass, particularly preferably 0.43 to 0.71 parts by mass, and most preferably 0.48 to 0.71 parts by mass per part by mass of the total of the (A) component and the (B) component, from the viewpoint of suppressing the appearance change of naproxen and ethenzamide. The content of the dry aluminum hydroxide gel relative to the total mass of the pharmaceutical composition is preferably 10 to 50 mass%, more preferably 20 to 50 mass%, and even more preferably 30 to 45 mass%.

[0022] <(c2) component> The component (c2) is glycine from the viewpoint of suppressing changes in appearance. The daily dose (amount) of glycine in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 60 to 900 mg, more preferably 180 to 900 mg. The content of glycine in the pharmaceutical composition of the present invention is preferably 0.01 to 5 parts by mass, more preferably 0.02 to 2 parts by mass, and particularly preferably 0.43 to 2 parts by mass, per part by mass of the total value of the components (A) and (B), from the viewpoint of suppressing changes in appearance due to naproxen and ethenzamide. The content of glycine is preferably 10 to 70% by mass, more preferably 20 to 70% by mass, even more preferably 25 to 70% by mass, and even more preferably 30 to 70% by mass, relative to the total mass of the pharmaceutical composition.

[0023] <(c3) component> As the component (c3), lactose, hydroxypropyl cellulose, and hypromellose are used to suppress changes in appearance. The effect of suppressing changes in appearance was not observed with other excipients such as potato starch, mannitol, crystalline cellulose, and sodium starch glycolate, and this effect is unique to the specific excipient of the present invention.

[0024] The hydroxypropyl cellulose of the present invention is a binder and is different from the low-substituted hydroxypropyl cellulose which is a disintegrant. The contents of lactose, hydroxypropyl cellulose, and hypromellose in the pharmaceutical composition of the present invention are each preferably 10 to 90% by mass, more preferably 10 to 80% by mass. From the viewpoint of suppressing changes in appearance of naproxen and ethenzamide, the contents of lactose, hydroxypropyl cellulose, and hypromellose are each preferably 0.01 to 10 parts by mass, more preferably 0.1 to 6.0 parts by mass, particularly preferably 0.13 to 6.0 parts by mass, and 0.13 to 2.0 parts by mass, per part by mass of the total value of components (A) and (B), respectively, in order to suppress changes in appearance of naproxen and ethenzamide.

[0025] The component (C) may be used alone or in appropriate combination of two or more kinds, and may be a coprecipitate, a coprecipitate product, or a mixed dry gel.

[0026] The pharmaceutical composition of the present invention is not particularly limited as long as it is in a dosage form specified in the General Rules for Preparations of the Japanese Pharmacopoeia, but from the viewpoint of appearance change, it is preferably a tablet, a powder, a fine granule, a granule, a pill, or a capsule, particularly preferably a tablet, a powder, a fine granule, or a granule, and most preferably a tablet. Tablets specified in the General Rules for Preparations of the Japanese Pharmacopoeia include orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, dissolving tablets, film-coated tablets, sugar-coated tablets, and laminated tablets. In addition, the tablets may be provided with a score line, a mark for improving identification, or a stamp. Furthermore, the tablets of the present preparation may be round tablets or irregular tablets. In addition, the present preparation may be a mini tablet.

[0027] When the components (A) and (B) of the present invention are blended so that they are substantially in contact with each other, the degree of change in appearance increases, and when the component (C) is added so that it coexists with these components, the change in appearance can be effectively suppressed. The phrase "component (A), component (B), and component (C) are substantially in contact with each other" refers to a state in which component (A), component (B), and component (C) are mixed together without being physically / chemically isolated. However, this does not exclude the blending of components other than component (A), component (B), and component (C), and the coexistence of other components is permitted. In addition, in the present invention, even if component (A), component (B), and component (C) are contained in separate granules, this is included in the state of being substantially in contact with each other, but it is not included in the case in which each component is blended in a separate granule and coated so that each granule does not come into contact with each other. In addition, when component (C) is contained only in the film coating layer of the tablet, the interaction between component (A) and component (B) cannot be suppressed, and therefore it is not included in the present invention.

[0028] The pharmaceutical composition of the present invention may contain other commonly used active ingredients, excipients, disintegrants, binders, flow agents, lubricants, acidulants, sweeteners, flavoring agents, refreshing agents, colorants, foaming agents, surfactants, plasticizers, coating agents, and the like, within the qualitative and quantitative ranges that do not impair the effects of the present invention.

[0029] Other active ingredients that can be incorporated into the pharmaceutical composition of the present invention include, for example, antipyretics, antihistamines, antitussives, bronchodilators, expectorants, hypnotics, sedatives, vitamins, amino acids, anti-inflammatory agents, gastric mucosa protective agents, herbal medicines, Chinese herbal medicine prescriptions, caffeines, and the like, and the pharmaceutical composition may contain one or more kinds selected from the group consisting of these.

[0030] Disintegrants that can be incorporated in the pharmaceutical composition of the present invention include low-substituted hydroxypropyl cellulose, sodium starch glycolate, crospovidone, carmellose, carmellose sodium, carmellose calcium, pregelatinized starch, etc., binders include hydroxypropyl cellulose, hypromellose, gelatin, pregelatinized starch, polyvinylpyrrolidone, pullulan, etc., and lubricants include sucrose fatty acid esters, hardened oils, stearic acid, magnesium stearate, calcium stearate, etc. In the present invention, flavors can be incorporated within the range that does not impair the effects of the present invention.

[0031] In addition, other basic compounds such as calcium hydrogen phosphate, synthetic aluminum silicate, and magnesium aluminometasilicate, as well as other excipients such as starch, mannitol, crystalline cellulose, and sodium starch glycolate, can also be blended within the scope of the present invention without impairing the effects of the present invention. The pharmaceutical composition of the present invention can be manufactured by a conventional method, and the method is not particularly limited. Manufacturing method of the tablet of the present invention After mixing the medicamentous active ingredient and the additives as described above in an appropriate mixer such as a mixer to manufacture a mixed powder for tablets, the mixed powder can be directly compressed and tableted, or the granules can be compressed and tableted. The manufacturing method of the granules can be a dry granulation method (slug method, roller compactor method) or a wet granulation method, and is not particularly limited, but is preferably a wet granulation method. As the wet granulation method, it may be manufactured by agitation granulation method, fluidized bed granulation method, extrusion granulation method, rolling granulation method, spray granulation method, etc., and is preferably agitation granulation method or fluidized bed granulation method. As a machine for compressing the mixed powder for tablets or the granules of the mixed powder, a single punch tableting machine, a rotary tableting machine, etc. can be used.

[0032] The packaging form of the pharmaceutical composition of the present invention is not particularly limited, but it can be filled into a commercially available container. From the viewpoint of the quality of the pharmaceutical product, an airtight container or a sealed container is preferable, and an airtight container is more preferable. Examples of the airtight container include glass bottles and plastic packaging. Examples of the plastic packaging include PTP packaging, PTP packaging including aluminum laminate film overlap, strip packaging, SP packaging, plastic bottles, aluminum individual packets (including stick packaging), pouch packaging, etc. EXAMPLES

[0033] The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to these examples.

[0034] (Preparation of solid dosage forms) (Examples 1 to 27, Comparative Examples 1 to 14) Each raw material component of the mixed powder was weighed according to the composition shown in Tables 1 and 2, and then mixed uniformly to obtain a preparation. (Test Example) <Evaluation method> The preparations of Examples 1 to 27, Comparative Examples 1 to 14, and Reference Example 1 were evaluated for storage stability by the following test method. Storage stability evaluation (appearance evaluation) The obtained preparations were stored in a sealed state, and the appearance (discoloration) after storage for 14 days under 6000 Lx conditions was visually observed in comparison with the product immediately after production. The degree of change in appearance of the present invention was evaluated on a 5-point scale. In addition, the evaluation was performed relative to the evaluation immediately after production, and the average was calculated from the following scores: 0 (no change), 1 (very slight change), 2 (slight change), 3 (change), and 4 (significant change). A score of 2 or less was considered acceptable. (result) The results of the appearance evaluation are shown in Tables 1 and 2.

[0035] [Table 1]

[0036] [Table 2]

[0037] As shown in Table 1, clear discoloration was observed in Comparative Example 1, which contained naproxen and ethenzamide, compared to Reference Example 1, which contained naproxen. Discoloration could be suppressed in Examples 1 to 17, which contained components c1 and c2 of the present invention. On the other hand, discoloration was not suppressed in Comparative Examples 2 to 4, which contained other basic compounds such as anhydrous calcium hydrogen phosphate, synthetic aluminum silicate, and magnesium aluminometasilicate. Comparative Examples 5 and 6 and Examples 18 and 19 demonstrate that discoloration could be suppressed by adding glycine even when the amounts of naproxen and ethenzamide were changed.

[0038] As shown in Table 2, discoloration could be suppressed by adding lactose, hydroxypropyl cellulose, and hypromellose to a formulation containing naproxen and ethenzamide. On the other hand, discoloration could not be suppressed by adding potato starch, mannitol, and crystalline cellulose. Discoloration was also suppressed when the amounts of naproxen and ethenzamide were changed.

[0039] (Examples 28 and 29) Each raw material component of the mixed powder was weighed according to the composition shown in Table 3, and then wet granulated to obtain granules. The obtained granules were compressed to obtain tablets.

[0040] [Table 3]

[0041] (Formulation example) Table 4 shows an example of a formulation.

[0042] [Table 4] [Industrial Applicability]

[0043] According to the present invention, it is possible to provide a pharmaceutical composition which contains naproxen or a salt thereof and has excellent storage stability.

Claims

1. (A) naproxen or a salt thereof, (B) ethenzamide or a salt thereof, and (C) at least one selected from the group consisting of the following (c1), (c2), and (c3): A pharmaceutical composition comprising: (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, and aluminum hydroxide gel; (c2) glycine (c3) at least one selected from the group consisting of lactose, hydroxypropyl cellulose, and hypromellose

2. 2. The pharmaceutical composition according to claim 1, wherein the content ratio of the component (A) to the component (B) is 0.125 to 150 parts by mass of the component (B) per 1 part by mass of the component (A).

3. 3. The pharmaceutical composition according to claim 1, wherein the content of the component (C) is 0.01 to 2 parts by mass per 1 part by mass of the total amount of the components (A) and (B).

4. The pharmaceutical composition according to claim 1 or 2, which is a solid formulation.

5. A method for inhibiting discoloration of a pharmaceutical composition containing (A) naproxen or a salt thereof and (B) ethenzamide or a salt thereof, comprising: A method for inhibiting discoloration of the pharmaceutical composition, comprising comprising comprising containing at least one member selected from the group consisting of the following (C) (c1), (c2), and (c3): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, magnesium hydroxide, synthetic hydrotalcite, and aluminum hydroxide gel; (c2) glycine (c3) at least one selected from the group consisting of lactose, hydroxypropyl cellulose, and hypromellose

Citation Information

Patent Citations

  • Pharmaceutical composition

    JP2018076305A

  • Cold remedy

    JP2018076306A

  • Oral solid composition

    JP2018076310A